What is Trintellix (Vortioxetine)?
Trintellix (vortioxetine) is a multimodal antidepressant approved by the FDA for treating major depressive disorder (MDD) in adults, distinguished by its unique mechanism that combines serotonin reuptake inhibition with direct effects on multiple serotonin receptors. 1
Mechanism of Action
Vortioxetine works through a distinctive "multimodal" mechanism that sets it apart from traditional SSRIs and SNRIs:
- Serotonin transporter (SERT) inhibition - blocks serotonin reuptake with high affinity (Ki=1.6 nM)
- 5-HT3, 5-HT7, and 5-HT1D receptor antagonism
- 5-HT1A receptor agonism
- 5-HT1B receptor partial agonism
This combination affects not only serotonin but also modulates norepinephrine, dopamine, acetylcholine, histamine, GABA, and glutamate neurotransmission 1, 2, 3. The clinical significance of these additional receptor activities beyond SERT inhibition remains under investigation, though they may contribute to effects on cognition.
Clinical Indications & Efficacy
FDA-approved indication: Major depressive disorder in adults 1
Efficacy data from clinical trials:
- Response rate: 53.2% (vs placebo 35.2%)
- Remission rate: 29.2% (vs placebo 19.3%)
- Effective in both short-term (8 weeks) and long-term (52 weeks) studies for preventing relapse/recurrence 4, 5
Dosing: Starting dose is 10 mg once daily, with a range of 5-20 mg/day. Can be taken without regard to food 1, 2
Unique Clinical Features
Cognitive effects: Multiple studies demonstrate improvements in working memory, episodic memory, cognitive flexibility, and executive function beyond what is typically seen with standard antidepressants 2, 6, 3, 4. This is particularly relevant since cognitive dysfunction commonly accompanies MDD.
Cardiovascular safety profile: Unlike some antidepressants, vortioxetine is not associated with QTc prolongation, significant blood pressure changes, heart rate alterations, or effects on platelet aggregation 1, 7. This makes it particularly suitable for patients with cardiovascular comorbidities.
Adverse Effects
Most common side effects:
- Nausea (most frequent, dose-related, typically occurs in first week then decreases) 1, 8
- Vomiting
- Constipation
- Dizziness
- Headache
- Somnolence
Serious but rare adverse effects to monitor:
- Suicidal thinking/behavior (FDA black box warning for patients ≤24 years)
- Serotonin syndrome (especially with concomitant serotonergic drugs)
- Hyponatremia (particularly in elderly or volume-depleted patients)
- Sexual dysfunction
- Abnormal bleeding (especially with NSAIDs/aspirin)
- Behavioral activation/agitation 1, 8
Newly identified post-marketing signals (not on original label): tinnitus, urinary retention, QT prolongation (rare), restless legs syndrome 8
Drug Interactions & Special Populations
Contraindications:
- Concurrent MAOI use (14-day washout required before starting vortioxetine; 21-day washout required before starting MAOI after stopping vortioxetine)
- Known hypersensitivity to vortioxetine 1
CYP2D6 poor metabolizers: Dose reduction recommended due to higher plasma concentrations 1
Elderly patients: No dose adjustment needed based on age alone, though increased hyponatremia risk 1
Pregnancy: May cause neonatal withdrawal symptoms or persistent pulmonary hypertension of the newborn (PPHN) if used in third trimester. Preliminary data from 56 first-trimester exposures showed no major malformations, though sample size limits conclusions 1, 9
Clinical Context & Positioning
While the 2008 ACP guidelines 10 recommend selecting second-generation antidepressants based on adverse effect profiles, cost, and patient preferences (as efficacy is generally similar across the class), vortioxetine was not available at that time. More recent evidence 6, 4, 5 suggests vortioxetine represents a good second-line option with potential advantages in patients with prominent cognitive symptoms or cardiovascular comorbidities.
Key monitoring: Assess response within 1-2 weeks of initiation; modify treatment if inadequate response after 6-8 weeks; continue for 4-9 months after satisfactory response for first episode 10
Discontinuation: Taper slowly to avoid withdrawal syndrome (similar to other serotonergic antidepressants) 1